Video

Michael Reff on Medically Integrated Dispensary in Value-Based Care

Michael Reff, executive director of National Community Oncology Dispensing Association (NCODA), discusses the role of the medically integrated dispensary in the transition to value-based payment models.

Michael Reff, executive director of National Community Oncology Dispensing Association (NCODA), discusses the role of the medically integrated dispensary in the transition to value-based payment models.

Transcript

Where do you see the role of the oncology pharmacist in value-based care?

I think the pharmacist or the medically integrated dispensary plays a tremendous role in those value-based pathways. In a sense that the medically integrated personnel need to ensure that there’s that continuity of care that we all talk about and to take additional cost of waste out of the system to ensure that the patient’s getting the right drug at the right time.

NCODA has developed a tool to help out practices capture cost avoidance and also waste that’s associated with prescriptions filled through specialty pharmacy. But more importantly, the cost avoidance tool captures the value in the amount of dispenses that are not completed in order to take cost away from the health system that would have been normally dispensed in a specialty pharmacy platform.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Rakendu Rajendran, MBBS
Vivek Bhalla, MD, Stanford University School of Medicine
Rayan Salih, MD, Northeast Georgia Health System
Deepak L. Bhatt, MD, MPH, MBA, FACC, FAHA, FESC, MSCAI, Mount Sinai Fuster Heart Hospital
Varsha Tanguturi, MD, MPH, Mass General Hospital
 Khush Kharidia, MD, UT Southwestern
Alexandra M. Trevino, MD, Northwestern Medicine
Andrew Kuykendall, MD, Moffitt Cancer Center
Dr Sundar Jagannath
David J. Maron, MD, FASPC, Stanford University School of Medicine
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo